Advancing patient care

Myriad Collaborative Research Registry – One of the largest pan-cancer registries freely available for research use.

Advancing patient care

Myriad Collaborative Research Registry – One of the largest pan-cancer registries freely available for research use.

Myriad is now accepting research project concept forms

The Myriad Collaborative Research Registry advances patient care by combining structured clinical data with genetic and genomic results. The overarching goal is to create an environment for improving and advancing cancer care.

The registry includes the following de-identified data:

  • >1.1 million patients included
  • Several represented cancer types
  • Gene expression, tumor, and germline testing results

Once granted access and trained, clinicians and researchers can use the research portal for immediate exploration. Queries and analyses conducted can foster further research opportunities. Download patient consent form.

Registry access form

Frequently asked questions

  • What is the purpose of the Myriad Collaborative Research Registry (MCRR)?
    To advance cancer care by providing research opportunities and fostering partnerships with clinicians.
  • What type of information will be in the MCRR?
    The registry is pre-loaded with de-identified data on >1.1 million patients. This includes genetic and genomic results along with clinical components from test requisition forms (TRF). Numerous Myriad tests are included across multiple cancer types. Immediate data exploration is available for researchers who have been trained on the MCRR dashboard.
  • What types of analysis can be done with data in MCRR?

    Once access is granted to the research portal, users will be able to carry out queries and analyses that will help inform and foster research opportunities.

    Some examples include:

    • Explore treatment and medical decision making across cohorts
    • Expand somatic-germline interactions and associations
    • Evaluate outcomes (in process) from different treatments based on ancestry, demographics, lifestyle, etc.
    • Compare individual data (in process) to aggregate group datasets
  • After I have access to MCRR how do I move forward with a research idea for publication?
    After completing a End User License Agreement and receiving training on the MCRR dashboard, you can access specific data. Complete a Research Concept Form outlining your proposed research idea. This will be evaluated by Myriad and, if approved, an IRB will be requested. Final approval of research activity is required by Myriad.
  • Where do I go for help with MCRR?

    The trainer orienting you to MCRR dashboard is available for support to navigate the registry. Contact [email protected] for triage to other experts as appropriate.

Explore Myriad Oncology’s genetic tests

  • Germline Tests

    Germline hereditary cancer test capable of identifying risk and providing insights for treatment options for 11 hereditary cancers. 

  • FDA-approved germline companion diagnostic test for patients with breast, ovarian, pancreatic and prostate cancer. 

  • HRD Status

    The most comprehensive FDA-approved tumor test that determines HRD status in women with ovarian cancer. 

  • Tumor Profiling

    Precise Tumor is a pan-cancer, comprehensive laboratory test that uses state-of-the-art, next-generation sequencing to discover and target important variants within tumors.

  • Prostate Cancer Prognostic Test

    Prolaris® is a molecular diagnostic test that helps determine the aggressiveness of a prostate cancer tumor to guide the best treatment decisions for prostate cancer patients.

Previous Test
    Next Test